[1]朱鹏飞,蒋国鹏,张云杰,等.益气养血方治疗非小细胞肺癌根治术后咳嗽疗效及对患者炎症因子的影响[J].陕西中医,2025,46(4):499-503.[doi:DOI:10.3969/j.issn.1000-7369.2025.04.014]
　ZHU Pengfei,JIANG Guopeng,ZHANG Yunjie,et al.Effect of Yiqi Yangxue prescription on cough after radical treatment of non-small cell lung cancer and its influence on inflammatory factors[J].,2025,46(4):499-503.[doi:DOI:10.3969/j.issn.1000-7369.2025.04.014]
点击复制

益气养血方治疗非小细胞肺癌根治术后咳嗽疗效及对患者炎症因子的影响
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
46
期数:
2025年4期
页码:
499-503
栏目:
临床研究
出版日期:
2025-04-20

文章信息/Info

Title:
Effect of Yiqi Yangxue prescription on cough after radical treatment of non-small cell lung cancer and its influence on inflammatory factors
作者:
朱鹏飞1; 蒋国鹏1; 张云杰2; 宿广峰1
(1.山东中医药大学附属医院胸外科,山东 济南 250014; 2.山东中医药大学附属医院普外科,山东 济南 250014)
Author(s):
ZHU Pengfei1; JIANG Guopeng1; ZHANG Yunjie2; SU Guangfeng1
(1.Department of Thoracic Surgery,Affiliated Hospital of Shandong University of Traditional Chinese Medicine,Jinan 250014,China; 2.Department of General Surgery,Affiliated Hospital of Shandong University of Traditional Chinese Medicine,Jinan 250014,China)
关键词:
非小细胞肺癌;  通调三焦;  益气养血方;  术后咳嗽;  疗效;  炎症因子
Keywords:
Non-small cell lung cancer;  Tongtiao Sanjiao;  Yiqi Yangxue prescription;  Postoperative cough;  Efficacy;  Inflammatory factor
分类号:
R 273
DOI:
DOI:10.3969/j.issn.1000-7369.2025.04.014
文献标志码:
A
摘要:
目的:基于“通调三焦”理论探究益气养血方治疗非小细胞肺癌(NSCLC)患者根治术后咳嗽的疗效。方法:选取150例行NSCLC根治术后咳嗽的患者,随机分为观察组(75例)和对照组(75例)。两组均采用常规止咳化痰治疗方案,在此基础上,对照组另予孟鲁司特钠片口服,观察组在对照组的基础上给予益气养血方治疗。比较两组患者临床疗效、中医证候积分、肺通气功能指标[肺活量(FVC)、呼气峰值流速(PEF)、第一秒用力呼气量占所有呼气量比例(FEV1/FVC)、肺一氧化碳弥散量(DLCO)、最大呼气中段流量(MMEF)、最大分钟通气量(MVV)]、炎症因子[高迁移率族蛋白B1(HMGB1)、CXC趋化因子配体10(CXCL10)和血清淀粉样蛋白A(SAA)],记录治疗期间不良反应发生情况。结果:治疗结束后,观察组整体疗效优于对照组,复发率和中医证候积分显著低于对照组(均P<0.05)。两组患者FVC、PEF、FEV1/FVC、DLCO、MMEF、MVV水平相较治疗前显著提升,观察组较对照组改善更为明显(均P<0.05)。两组炎症因子HMGB1、CXCL10、SAA水平较治疗前显著降低,且观察组低于对照组(均P<0.05)。两组不良反应发生率比较差异无统计学意义(P>0.05)。结论:益气养血方治疗NSCLC患者根治术后咳嗽疗效显著,可有效降低中医证候积分,增强肺通气功能,降低炎症反应,药物安全性较好。
Abstract:
Objective:Based on the theory of “Tongtiao Sanjiao” to explore the therapeutic effect of Yiqi Yangxue prescription on cough after radical surgery in patients with non-small cell lung cancer(NSCLC).Methods:150 patients with cough after undergoing radical resection for NSCLC were selected.By random coin tossing method,the participants were divided into observation group(digit side,75 cases)and control group(flower side,75 cases).Both groups were treated with conventional cough relief and phlegm resolving treatment.On this basis,the control group was additionally given montelukast sodium tablets,while the observation group was added with Yiqi Yangxue prescription on the basis of the control group.The clinical efficacy,TCM syndromes scores,pulmonary ventilation function indicators [forced vital capacity(FVC),peak expiratory flow(PEF),proportion of forced expirations in the first second to forced vital capacity(FEV1/FVC),lung carbon monoxide diffusing capacity(DLCO),maximum mid-expiratory flow(MMEF),and maximum voluntary ventilation(MVV)],inflammatory factors [high-mobility group box-1 protein(HMGB1),CXC chemokine ligand 10(CXCL10)and serum amyloid A(SAA)] were compared between the two groups before and after treatment,and the occurrence of adverse reactions during treatment was recorded.Results:After the end of treatment,the efficacy rate of the treatment in the observation group was markedly superior to that of the control group,and both the relapse rate and the scores for TCM symptoms were considerably lower in the observation group compared to the control group(all P<0.05).The levels of pulmonary ventilation function indicators FVC,PEF,FEV1/FVC,DLCO,MMEF and MVV in the two groups of patients were significantly improved compared with those before treatment,the enhancements observed in the observation group were notably more pronounced and surpassed those of the control group with statistical significance(all P<0.05).The levels of inflammatory factors HMGB1,CXCL10 and SAA in two groups were significantly lower than before treatment,and the observation group was lower than the control group(all P<0.05).There was no significant difference in the incidence of adverse reactions between groups(P>0.05).Conclusion:Yiqi Yangxue prescription has significant curative effect on cough after radical treatment of NSCLC patients,which can effectively reduce TCM syndrome scores,enhance lung ventilation function,reduce inflammation,and has good drug safety.

参考文献/References:

[1] 石玉琳,刘嘉懿,李军,等.非小细胞肺癌中医证候的舌脉诊参数特征[J].中华中医药杂志,2022,37(6):3395-3400.
[2] 蒋立峰,桑锋,刘怀民,等.清肺化瘀解毒方治疗非小细胞肺癌吉非替尼获得性耐药临床疗效观察[J].中华中医药杂志,2023,38(11):5575-5578.
[3] 吴琼茜,刘苓霜,姜怡,等.中医辨证疗法联合埃克替尼治疗晚期非小细胞肺癌疗效观察[J].中国中西医结合杂志,2017,37(9):1054-1058.
[4] 魏玉林,王淑美.中医治疗肺癌咳嗽临床研究[J].中华中医药学刊,2016,34(1):186-188.
[5] 郭雯,冯贞贞,王露,等.基于文献的肺癌常见中医证候研究[J].中医杂志,2021,62(16):1447-1454.
[6] 吴敏,黄敏娜,刘云鹤,等.贾英杰从三焦“黜浊培本”辨治肺癌经验[J].中华中医药杂志,2023,38(2):683-686.
[7] 李文涛,刘云鹤,潘攀,等.调益三焦针灸法对中晚期非小细胞肺癌癌因性疲乏的疗效及免疫功能的影响[J].针刺研究,2020,45(12):1000-1005.
[8] 杨芮姗,谷丰,高健.基于“温三焦之阳,理气化痰通脉”法则论治房室传导阻滞[J].陕西中医,2024,45(9):1230-1232,1236.
[9] 中华中医药学会肺系病分会,世界中医药学会联合会肺系病专业委员会.咳嗽中医诊疗专家共识意见(2021)[J].中医杂志,2021,62(16):1465-1472.
[10] 中国抗癌协会癌症康复与姑息治疗专业委员会.肺癌相关性咳嗽诊疗中国专家共识[J].中华医学杂志,2021,101(35):2751-2759.
[11] 左明焕,胡凯文,陈信义.非小细胞肺癌患者手术前后中医证候特征研究[J].中医杂志,2002,43(8):615-617.
[12] 赵国桢,宗星煜,赵学尧,等.《中医病证诊断与疗效评价规范制修订通则》解读[J].中国中医基础医学杂志,2024,30(8):1294-1297.
[13] KLIMCZAK M,PIEKIELNY D,ANTCZAK A,et al.Effectiveness of pulmonary rehabilitation in patients with chronic obstructive pulmonary disease after lobectomy due to non-small cell lung cancer:A single-center retrospective study[J].Adv Respir Med,2021,89(3):247-253.
[14] 康艳,李耀辉,李哲.论陈士铎从脏腑五行生克之变治疗内伤咳嗽[J].陕西中医,2020,41(3):360-363.
[15] 甘露,毕佳慧,陶大虎,等.肺癌术后咳嗽案[J].中国针灸,2022,42(11):1245-1246.
[16] 张潇潇,朱潇雨,朱广辉,等.基于“诸痿喘呕,皆属于上”探讨心肺同治在肺癌症状群的应用[J].中华中医药杂志,2022,37(8):4833-4835.
[17] 段海婧,宁艳梅,吴国泰,等.非小细胞肺癌中医证型及用药规律的网络构建及可视化分析[J].中药药理与临床,2023,39(10):87-92.
[18] 黄海平,张天慧,雷晓明,等.张崇泉基于“三焦分治,引火归元”治逸病临证经验[J].国际中医中药杂志,2023,45(3):363-366.
[19] 王鹏,黄梅艳,徐辉,等.经皮穴位电刺激对胸腔镜肺癌术后咳嗽的影响[J].中国针灸,2024,44(5):521-525.
[20] 韩景献.再论三焦及三焦气化[J].中医杂志,2016,57(23):2061-2063.
[21] 刘晓菊,姚芮,杨学知,等.早期非小细胞肺癌胸腔镜下肺亚段切除术与肺段切除术治疗效果比较[J].陕西医学杂志,2024,53(8):1069-1072.
[22] 崔和勤,李占军,杨秋,等.黄芪对肠缺血-再灌注损伤过程中肺表面活性物质及LPO含量的影响[J].中国新药与临床杂志,2000,19(4):270-272.
[23] 傅阳,袁培培,李潘营,等.基于GnRH探讨升浮药麻黄、沉降药葶苈子干预肺水肿作用差异[J].中药药理与临床,2024,40(2):55-62.
[24] 万海同,何昱,周惠芬,等.清解宣透肺卫方银花平感颗粒治疗上呼吸道感染邪郁肺卫证的安全性和有效性研究:一项随机双盲、阳性药物平行对照、多中心临床试验[J].中国中西医结合急救杂志,2017,24(6):602-607.
[25] 蔡蓉蓉,施平平,顾春燕.高迁移率族蛋白B1巨噬细胞转移抑制因子联合CXC亚家族趋化因子16对高危型HPV感染患者诊断价值[J].河北医学,2024,30(7):1160-1165.
[26] 李梅,蒋锦梅,欧大明,等.白术多糖对类风湿性关节炎大鼠的抗炎作用及TLR4/NF-κB信号通路的影响[J].安徽医科大学学报,2022,57(4):552-557.
[27] 许光远,张晓明,贾春玲.桑叶黄酮对糖尿病小鼠胰岛素抵抗及炎症反应的作用机制[J].中国实验方剂学杂志,2023,29(16):52-57.
[28] 刘淇,高铭,吕红君,等.防风乙醇提取物对LPS所致小鼠炎症模型的抗炎作用及机制研究[J].中国中药杂志,2021,46(18):4800-4807.

相似文献/References:

[1]刘月芬,刘小红,于明军,等.清金化痰汤治疗非小细胞肺癌临床研究[J].陕西中医,2019,(2):229.
　LIU Yuefen,LIU Xiaohong,YU Mingjun,et al.Clinical observation of nonsmall cell lung cancer patients treated with Qingjin Huatan decoction[J].,2019,(4):229.
[2]陈姣红,古红莉,员建中,等.参术扶正抗癌汤联合化疗及三维适形放疗对晚期非小细胞肺癌患者 血清T细胞亚群水平及生存质量的影响*[J].陕西中医,2019,(5):564.
[3]张栓宝,严宁娟△,张燕平.复方斑蝥胶囊对非小细胞肺癌患者围术期血清炎症因子及免疫功能的影响[J].陕西中医,2019,(7):890.
[4]任宝中,李 媛△.益气化瘀方配合化疗治疗晚期非小细胞肺癌临床研究*[J].陕西中医,2019,(8):1036.
　REN Baozhong,LI Yuan..Application effect of TP chemotherapy Plus Yiqi Huayu decoction in advanced Non-small cell lung cancer patients[J].,2019,(4):1036.
[5]任东峰,孙国芳△.六君祛痰解毒汤联合化疗治疗非小细胞肺癌疗效〖JZ〗及对患者血管内皮生长因子的影响[J].陕西中医,2020,(1):63.
[6]刘 婷,李 洋,石志红.灯盏花素对非小细胞肺癌A549细胞的作用及机制研究[J].陕西中医,2021,(10):1363.[doi:DOI:10.3969/j.issn.1000-7369.2020.10.009]
　LIU Ting,LI Yang,SHI Zhihong.Effects of breviscapine on proliferation and apoptosis of non-small cell lung cancer A549 cells[J].,2021,(4):1363.[doi:DOI:10.3969/j.issn.1000-7369.2020.10.009]
[7]肖 凌,王 洋,钱建新,等.生脉饮合沙参麦冬汤联合西药治疗晚期非小细胞肺癌疗效研究[J].陕西中医,2021,(12):1696.[doi:DOI:10.3969/j.issn.1000-7369.2020.12.010]
[8]陈香梅,刘太锋,杨 明,等.复方苦参注射液联合化疗治疗非小细胞肺癌疗效研究[J].陕西中医,2021,(12):1700.[doi:DOI:10.3969/j.issn.1000-7369.2020.12.011]
[9]王理槐,孙银辉,张领兄,等.基于Wnt/β-catenin信号通路探讨血府逐瘀汤在非小细胞肺癌EGFR-TKI获得性耐药中的作用[J].陕西中医,2022,(4):427.[doi:DOI:10.3969/j.issn.1000-7369.2022.04.004]
　WANG Lihuai,SUN Yinhui,ZHANG Lingxiong,et al.Efficacy of Xuefu Zhuyu decoction in EGFR-TKI-Acquired resistance of non-small cell lung carcinoma based on the Wnt/β-catenin signaling pathway[J].,2022,(4):427.[doi:DOI:10.3969/j.issn.1000-7369.2022.04.004]
[10]屈 直,王 芬,李志明,等.二陈汤对Lewis肺癌移植瘤生长及Hedgehog通路蛋白表达的影响[J].陕西中医,2022,(5):555.[doi:DOI:10.3969/j.issn.1000-7369.2022.05.003]
　QU Zhi,WANG Fen,LI Zhiming,et al.Effect of Erchen decoction on the expression of Hedgehog pathway protein in Lewis lung cancer transplanted tumor[J].,2022,(4):555.[doi:DOI:10.3969/j.issn.1000-7369.2022.05.003]

备注/Memo

备注/Memo:
[基金项目]山东省自然科学基金资助面上项目(ZR2021MH297)
更新日期/Last Update: 2025-04-08